- Conditions
- Melanoma, Melanoma Stage III
- Interventions
- PET Scan, Nivolumab, Ipilimumab, Surgical Resection of Melanoma
- Diagnostic Test · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 2,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
- Interventions
- Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 13
- States / cities
- Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
- Interventions
- Poly-ICLC
- Drug
- Lead sponsor
- Nina Bhardwaj
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
- Interventions
- [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
- Drug · Diagnostic Test
- Lead sponsor
- David Bushnell
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Malignant Carcinoid Syndrome
- Interventions
- lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma
- Interventions
- Decitabine, Pegylated Interferon Alpha-2b
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Cancers
- Interventions
- Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Interventions
- SOM230, RAD001
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Neuroendocrine Tumors
- Interventions
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Ipilimumab, Nivolumab, Prednisone, Tacrolimus
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
- Interventions
- 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
- Interventions
- IPI-549 (eganelisib), Nivolumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 11
- States / cities
- San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes, in vitro-treated peripheral blood stem cell transplantation, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, filgrastim, aldesleukin
- Drug · Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Melanoma, Skin Cancer, Neoplasm
- Interventions
- ADI PEG 20
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Melanoma
- Interventions
- Skin Self Examination Information and ABCDE Rule
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Maywood, Illinois • Lebanon, New Hampshire
- Conditions
- Melanoma
- Interventions
- Trametinib, Dabrafenib, INCB039110
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neuroendocrine Tumors
- Interventions
- [90]Y-DOTATOC
- Drug
- Lead sponsor
- Sandeep Laroia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, incomplete Freund's adjuvant, interleukin-2 gene, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Melanoma, BRAF V600 Mutation Positive
- Interventions
- Itraconazole, Rifampin, Vemurafenib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
- Interventions
- PRT1419
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 412
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
- Conditions
- Anxiety
- Interventions
- Normal Education Material, Vignette
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Neuroendocrine Tumors
- Interventions
- Surufatinib
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 12 Years and older
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Baltimore, Maryland • Detroit, Michigan + 8 more